Document is current
Any future updates will be listed below
-
Authors
Qian, Xiaowen
Zhang, Dufei
Li, Kai
Chen, Weiming
Zhuang, Peijun
Wang, Hongsheng
Lei, Zhixian
Li, Yan
Eldridge, James
Dong, Kuiran
Zhai, Xiaowen
-
Funding
Funding for this research was provided by:
Cyrus Tang Foundation (ZSBK0070)
Shanghai Fudan University Education Development Foundation (ZSBK0046)
Shanghai Municipal Committee of Science and Technology (21Y31900302)
- License Information
-
More Information
Article History
Accepted: 12 November 2024
First Online: 20 December 2024
Declarations
:
: Funding was received from the National Key R&D Program of China (2023YFC2706301), the National Key R&D Program of China (2022YFC2705003), the National Natural Science Foundation of China (82141125), and the Shanghai Hospital Development Center (SHDC12023109).
: James Eldridge reports employment with Y-mAbs Therapeutics Inc. Xiaowen Qian, Dufei Zhang, Kai Li, Weiming Chen, Peijun Zhuang, Hongsheng Wang, Zhixian Lei, Yan Li, Kuiran Dong, and Xiaowen Zhai have no conflicts of interest that are directly relevant to the content of this article.
: The Institutional Review Board of the Hainan Women and Children’s Medical Center of Fudan University approved the study on 2021/07/02 with ethics approval number HNWCMC 伦审 2021年第[84]号.
: Written informed consent was obtained from all patients before naxitamab treatment.
: Not applicable.
: Not applicable.
: Not applicable.
: XQ: contributions to the conception or design of the work; drafting the work. DZ: contribution to acquisition of data for the work; reviewing it critically for important intellectual content. KL: contributions to interpretation of data for the work; reviewing it critically for important intellectual content. WC: contributions to interpretation of data for the work; reviewing it critically for important intellectual content. PZ: contributions to interpretation of data for the work; reviewing it critically for important intellectual content. HW: contributions to interpretation of data for the work; reviewing it critically for important intellectual content. ZL: contribution to acquisition of data for the work; contributions to interpretation of data for the work. YL: contribution to acquisition of data for the work. JE: contribution to analysis of data for the work. KD: final approval of the version to be published; agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. XZ: final approval of the version to be published; agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All the authors have read and approved the manuscript of the last version to be published.
